Year of diagnosis | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 |
---|---|---|---|---|---|---|
Crude incidence rate (IR) | ||||||
Overall | 170.99 | 166.88 | 159.45 | 177.99 | 170.83 | 171.37 |
TN | 15.88 | 16.80 | 14.23 | 13.70 | 16.28 | 16.48 |
HR+/HER2+ | 9.59 | 11.10 | 10.36 | 11.41 | 9.38 | 13.00 |
HR+/HER2- | 110.23 | 106.95 | 107.13 | 121.43 | 118.90 | 114.76 |
HR-/HER2+ | 5.65 | 5.28 | 5.65 | 6.75 | 6.59 | 6.45 |
World Standardized IR | ||||||
Overall | 116.84 | 113.77 | 109.67 | 119.35 | 114.59 | 113.89 |
TN | 11.96 | 13.00 | 10.43 | 9.85 | 11.22 | 12.00 |
HR+/HER2+ | 6.70 | 8.26 | 8.37 | 8.74 | 7.26 | 10.03 |
HR+/HER2- | 75.78 | 73.03 | 72.73 | 82.07 | 79.68 | 75.21 |
HR-/HER2+ | 4.10 | 4.08 | 4.53 | 5.00 | 4.94 | 4.48 |
Europe Standardized IR | ||||||
Overall | 154.27 | 149.78 | 142.02 | 157.86 | 150.87 | 149.10 |
TN | 15.35 | 15.95 | 13.11 | 12.52 | 13.85 | 14.85 |
HR+/HER2+ | 8.37 | 10.65 | 10.20 | 11.18 | 9.32 | 11.88 |
HR+/HER2- | 100.97 | 96.98 | 95.48 | 108.85 | 106.15 | 100.69 |
HR-/HER2+ | 4.90 | 4.99 | 5.35 | 6.33 | 6.09 | 5.61 |